Your browser doesn't support javascript.
loading
Development of shielding evaluation and management program for O-ring type linear accelerators.
Choi, Dong Hyeok; Ahn, So Hyun; Kim, Dong Wook; Choi, Sang Hyoun; Ahn, Woo Sang; Kim, Jihun; Kim, Jin Sung.
Afiliação
  • Choi DH; Department of Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Ahn SH; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, South Korea.
  • Kim DW; Ewha Medical Research Institute, School of Medicine, Ewha Womans University, Seoul, South Korea. mpsohyun@gmail.com.
  • Choi SH; Department of Medicine, Yonsei University College of Medicine, Seoul, Korea. joocheck@gmail.com.
  • Ahn WS; Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, South Korea. joocheck@gmail.com.
  • Kim J; Department of Radiation Oncology, Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
  • Kim JS; Department of Radiation Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, Republic of Korea.
Sci Rep ; 14(1): 10719, 2024 05 10.
Article em En | MEDLINE | ID: mdl-38729975
ABSTRACT
The shielding parameters can vary depending on the geometrical structure of the linear accelerators (LINAC), treatment techniques, and beam energies. Recently, the introduction of O-ring type linear accelerators is increasing. The objective of this study is to evaluate the shielding parameters of new type of linac using a dedicated program developed by us named ORSE (O-ring type Radiation therapy equipment Shielding Evaluation). The shielding evaluation was conducted for a total of four treatment rooms including Elekta Unity, Varian Halcyon, and Accuray Tomotherapy. The developed program possesses the capability to calculate transmitted dose, maximum treatable patient capacity, and shielding wall thickness based on patient data. The doses were measured for five days using glass dosimeters to compare with the results of program. The IMRT factors and use factors obtained from patient data showed differences of up to 65.0% and 33.8%, respectively, compared to safety management report. The shielding evaluation conducted in each treatment room showed that the transmitted dose at every location was below 1% of the dose limit. The results of program and measurements showed a maximum difference of 0.003 mSv/week in transmitted dose. The ORSE program allows for the shielding evaluation results to the clinical environment of each institution based on patient data.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Aceleradores de Partículas / Proteção Radiológica Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Aceleradores de Partículas / Proteção Radiológica Idioma: En Ano de publicação: 2024 Tipo de documento: Article